Pharma & Biotech - Page 28

Daiichi Sankyo has revised its full-year guidance upward after discovering an accounting error that understated operating profit in its fiscal year 2025 results. The Japanese pharmaceutical company identified a mistake in the

The pharmaceutical industry continues to wrestle with supply chain vulnerability, a problem that has intensified steadily since pandemic-era drug shortages first exposed critical weaknesses. Geopolitical tensions, tariff uncertainty, and ongoing national security

STEPLogic Trace is positioning itself as a key solution for pharmaceutical companies navigating the complex requirements of DSCSA-compliant supply chains. The platform helps pharmaceutical supply chains produce certified EPCIS outputs, enabling companies

Alnylam Pharmaceuticals (ALNY) shares collapsed nearly 28% on Thursday, closing at $206.88 after the company reported disappointing Amvuttra sales and slashed its full-year outlook. The RNA interference therapy crossed the $1 billion

Pharmaceutical companies are being urged to assess whether their serialization systems can keep pace with expanding business demands and regulatory requirements. Serialization has become a cornerstone of modern pharmaceutical supply chain management,

Pfizer (PFE) has announced that its drug Litfulo met primary goals in two large late-stage studies for nonsegmental vitiligo, the most common form of the skin-pigmentation disorder. Both studies showed significantly more

The US Food and Drug Administration has moved into full enforcement of the Drug Supply Chain Security Act after an 18-month stabilisation grace period concluded. The enforcement shift marks a significant turning

Ember LifeSciences has entered into a capital and business alliance with Alfresa Corporation to strengthen pharmaceutical cold chain logistics across Japan. Alfresa Corporation is a subsidiary of Alfresa Holdings Corporation, which holds

Pharmaceutical manufacturers are accelerating investment in direct-to-patient models as policy shifts and rising consumer expectations reshape the industry landscape. Chip Parkinson, CEO of Gifthealth, says the momentum behind these integrated models has

Incyte Corporation has raised its full-year 2026 Opzelura net sales guidance to between $1.05 billion and $1.1 billion following a landmark settlement with the Centers for Medicare & Medicaid Services. The agreement